RSV vaccine trial results from GSK show strong efficacy
GSK on Thursday announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and […]
RSV vaccine trial results from GSK show strong efficacy Read More »